Pipeline

Program Target/MOA Indication Research Preclinical Phase 1 Phase 2 Phase 3
tRNA synthetase programs
Efzofitimod NRP2 modulator Pulmonary Sarcoidosis1
 
SSc-ILD
 
Other ILD
(CTD-ILD; CHP)
 
ATYR0101 LTBP1 modulator Fibrosis
 
ATYR0750 FGFR4 modulator Liver Disorders
 
Monoclonal antibody programs
ATYR2810 NRP2/VEGF antagonist Solid Tumors
 
ATYR4010 NRP2/CCR7 antagonist Autoimmune Disease
 
Program/
Target
Indication Phase
tRNA synthetase programs
Efzofitimod (ATYR1923)
NRP2 modulator
Pulmonary Sarcoidosis1 Phase 3
SSc-ILD Phase 2
Other ILD (CTD-ILD; CHP) Phase 1
ATYR0101
LTBP1 modulator
Fibrosis Research
ATYR0750
FGFR4 modulator
Liver Disorders Research
Monoclonal antibody programs
ATYR2810
NRP2/VEGF antagonist
Fibrosis Research
ATYR4010
NRP2/CCR7 antagonist
Autoimmune Disease Preclinical

(1) In partnership with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILD in Japan
SSc-ILD = Scleroderma-related ILD; CTD-ILD = Connective Tissue Disease-ILD; CHP = Chronic Hypersensitivity Pneumonitis

© 2007 - 2023   aTyr Pharma.   Legal   Privacy Policy